Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
S I Abrams, S N Khleif, E S Bergmann-Leitner...
https://pubmed.ncbi.nlm.nih.gov/9514698/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-11-03
110
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are studying a new gene therapy for adults aged 18 to 72 with advanced solid tumors that express the KRAS G12V mutation and who have the HLA-A*1101 marker. This therapy involves genetically modifying a patients own white blood cells to target tumors. The study aims to evaluate the safety of this treatment and to see if it can shrink tumors in people whose cancers have progressed after standard therapies. Participants will first undergo leukapheresis to collect their peripheral blood lymphocytes, which will then be genetically modified in the lab with an anti-KRAS G12V murine T-cell receptor. Before receiving the modified cells, participants will receive a preparative chemotherapy regimen with cyclophosphamide and fludarabine over several days to prepare their body. On day 0, the modified cells will be infused back intravenously, followed by high-dose aldesleukin a drug to activate the cells administered multiple times over up to 3 days. Additional supportive care includes a drug to boost white blood cell counts and long-term antibiotics for at least six months. During the study, participants will be hospitalized for 1 to 2 weeks for recovery and monitoring with frequent lab and blood tests. Afterwards, they will have follow-up visits every few months for two years, which may include physical exams, imaging scans, blood draws, and possibly additional leukapheresis. Blood samples will be collected over several years to monitor health and treatment effects. The study measures tumor response and treatment-related side effects, with evaluations starting about six weeks after the cell infusion and continuing regularly thereafter.
CONDITIONS
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
N
NCI SB Immunotherapy Recruitment Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | G12V-mutated RAS TCR-Engineered Cell Therapy | Current-Care Therapy for Advanced Gastrointestinal Cancers |
|---|---|---|
| What it is | A treatment protocol using patients' own peripheral blood lymphocytes genetically altered to target tumors with the G12V mutation in RAS, given after lymphodepleting cyclophosphamide and fludarabine chemotherapy, followed by high-dose aldesleukin (IL-2) support. | Recommended therapies include chemotherapy regimens, targeted agents, and best supportive care for patients with advanced gastrointestinal, pancreatic, or colorectal cancers no longer responsive to earlier lines. Options may include trifluridine/tipiracil, regorafenib, or combination therapy as appropriate to cancer type and molecular markers. |
| Role in the study | Single investigational treatment group; all participants receive the full regimen, with possible dose variation in the dose escalation and expansion phases. | Not included in the trial; represents current recommended care choices for similar patients after exhausting standard therapies. |
| Main use or purpose | Studied as a potential anti-tumor treatment for adults with advanced gastrointestinal, pancreatic, colon, or gastric cancers harboring the G12V RAS mutation, after prior standard treatments. | Palliative management aimed at controlling cancer progression and symptoms, tailored according to previous treatments, tumor characteristics, and patient status. |
| How it is given or performed | Participants receive intravenous cyclophosphamide and fludarabine for lymphodepletion, then an infusion of genetically modified T cells (engineered to recognize G12V RAS), followed by high-dose aldesleukin (IL-2) administered intravenously every 8 hours for up to 3 days. | Systemic therapies such as trifluridine/tipiracil or regorafenib are given orally. Other agents (chemotherapy or targeted drugs) may be administered intravenously, depending on regimen and patient status. |
| Evidence status | Efficacy and safety are under investigation; no outcomes are posted in the registry and there is limited peer-reviewed outcome evidence for this specific TCR-engineered product in the target population. | Effectiveness and safety of standard therapies are supported by randomized clinical trials and are included in national and international guidelines. |
| Important limitations | Has only been evaluated in small, early-phase cohorts, with limited published results. Potential for adverse effects from lymphodepleting chemotherapy, engineered T cells, or high-dose aldesleukin. Access is strictly limited to clinical trials for selected patients. | Standard options for advanced gastrointestinal cancers after prior therapy often achieve modest benefits, and cumulative toxicity or frailty can limit further systemic therapy. Comorbidities and tumor biology further restrict effective therapy choices. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 days
Participants receive chemotherapy with cyclophosphamide and fludarabine over several days to prepare the body for the cell infusion.
Daily infusions during this period
Duration - 4 to 5 days
Participants receive the genetically modified anti-KRAS G12V mTCR cells intravenously followed by high-dose aldesleukin to activate the cells over up to 3 days.
Multiple infusions and injections during this period
Duration - 1 to 2 weeks
Participants stay in the hospital for 1 to 2 weeks for recovery with lab and blood tests. They also receive a white blood cell boosting injection and take antibiotics for at least 6 months.
Daily monitoring during hospitalization
Duration - Up to 2 years and beyond
Participants have follow-up visits every few months for two years and additional visits as needed. Visits include physical exams, imaging, lab tests, and sometimes blood collection or leukapheresis.
Visits every few months for 2 years, then as determined by doctor
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
S I Abrams, S N Khleif, E S Bergmann-Leitner...
https://pubmed.ncbi.nlm.nih.gov/9514698/Qiong J Wang, Zhiya Yu, Kayla Griffith...
https://pubmed.ncbi.nlm.nih.gov/26701267/Jeremy L Davis, Marc R Theoret, Zhili Zheng...
https://pubmed.ncbi.nlm.nih.gov/21138872/National Cancer Institute (NCI)
Lead Sponsor